Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report

References

• UNAIDS. [accessed 2022 May 20]. https://www.unaids.org/en/resources/documents/2021/HIV_COVID-19_brochure.
   Google Scholar
• Netto LC, Ibrahim KY, Picone CM, Alves AP, Aniceto EV, Santiago MR, Parmejani PS, Aikawa NE, Medeiros-Ribeiro AC, Pasoto SG, et al. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet HIV. 2022;9(5):1–4. doi:10.1016/S2352-3018(22)00033-9.
   Web of Science ®Google Scholar
• Ao L, Lu T, Cao Y, Chen Z, Wang Y, Li Z, Ren X, Xu P, Peng M, Chen M, et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV. Emerg Microbes Infect. 2022;11(1):1126–1134. doi:10.1080/22221751.2022.2059401.
   PubMed Web of Science ®Google Scholar
• Huang X, Yan Y, Su B, Xiao D, Yu M, Jin X, Duan J, Zhang X, Zheng S, Fang Y, et al. Comparing immune responses to inactivated vaccines against SARS-CoV-2 between people living with HIV and HIV-negative individuals: a cross-sectional study in China. Viruses. 2022;14(2):277. doi:10.3390/v14020277.
   PubMed Web of Science ®Google Scholar
• Kerneis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boëlle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(8):1130–1139. doi:10.1093/cid/cit937.
   PubMed Web of Science ®Google Scholar
• Costa C, Migliore E, Galassi C, Scozzari G, Ciccone G, Coggiola M, Pira E, Scarmozzino A, La Valle G, Cassoni P, et al. Factors influencing level and persistence of anti SARS-CoV-2 IgG after BNT162b2 vaccine: evidence from a large cohort of healthcare workers. Vaccines. 2022;10(3):474. doi:10.3390/vaccines10030474.
   Web of Science ®Google Scholar
• Wondimeneh Y, Alem M, Asfaw F, Belyhun Y. HBV and HCV seroprevalence and their correlation with CD4 cells and liver enzymes among HIV positive individuals at University of Gondar Teaching Hospital, Northwest Ethiopia. Virol J. 2013;10(1):171. doi:10.1186/1743-422X-10-171.
   PubMed Web of Science ®Google Scholar
• Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatol (Baltimore, Md). 2009;49(5 Suppl):S138–145. doi:10.1002/hep.22883.
   PubMed Web of Science ®Google Scholar
• Kwofie TB, Adigbli D, Osei-Yeboah J, Ativi E, Lokpo SY. Hepatitis B and C infections in HIV-1 patients on combination antiretroviral therapy (cART) in Ghana: implications for immunologic recovery, clinical response to treatment, and hepatotoxicity. Heliyon. 2021;7(6):e07172. doi:10.1016/j.heliyon.2021.e07172.
   PubMed Web of Science ®Google Scholar
• Maitha GM, Kikuvi G, Wanzala P, Kirui F. Influence of hepatitis B virus co-infection on virological and immunological response to antiretroviral treatment among HIV patients attending comprehensive care clinics in Makueni County, Kenya. Pan Afr Med J. 2021;38:103. doi: 10.11604/pamj.2021.38.103.25793.
   PubMed Web of Science ®Google Scholar
• Malagnino V, Cerva C, Teti E, Campogiani L, Compagno M, ForoghiBil L, Saderi L, Armenia D, Salpini R, Svicher V, et al. Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers. Sci Rep. 2021;11(1):3965. doi:10.1038/s41598-021-83616-z.
   PubMed Web of Science ®Google Scholar
• Peng X, Ouyang J, Isnard S, Lin J, Fombuena B, Zhu B, Routy JP. Sharing CD4+T cell loss: when COVID-19 and HIV collide on immune system. Front Immunol. 2020;11:596631. doi:10.3389/fimmu.2020.596631.
   PubMed Web of Science ®Google Scholar
• El Chaer F, El Sahly HM. Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity. Am J Med. 2019;132(4):437–446. doi:10.1016/j.amjmed.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Tan Y, Zou S, Ming F, Zhang Z, Xing Z, Wu S, Guo W, Tang W, Liang K. Early efficacy and safety of the third dose inactivated COVID-19 vaccine among people living with HIV. J J Acquir Immune Defic Syndr. 2022;90(3):e1–e3. doi:10.1097/QAI.0000000000002953.
   PubMed Web of Science ®Google Scholar
• Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczyńska M, Navarro LM, Scherpbier HJ, Heath PT. Guidance on vaccination of HIV-infected children in Europe. HIV Med. 2012;13(6):333–336. doi:10.1111/j.1468-1293.2011.00982.x.
   PubMed Web of Science ®Google Scholar
• Duro R, Rocha-Pereira N, Figueiredo C, Piñeiro C, Caldas C, Serrão R, Sarmento A. RoutineCD4 monitoring in HIV patients with viral suppression: is it really necessary? a Portuguese cohort. J Microbiol Immunol Infect. 2018;51(5):593–597. doi:10.1016/j.jmii.2016.09.003.
   PubMedGoogle Scholar
• Fritzsche C, Bergmann L, Loebermann M, Glass A, Reisinger EC. Immune response to hepatitis a vaccine in patients with HIV. Vaccine. 2019;37(16):2278–2283. doi:10.1016/j.vaccine.2019.018.064.
   PubMed Web of Science ®Google Scholar
• Song JY, Cheong HJ, Noh JY, Choi MJ, Yoon JG, Kim WJ. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count. Hum Vaccin Immunother. 2020;16(1):169–175. doi:10.1080/21645515.2019.1643677.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. doi:10.1056/NEJMoa1506816.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhang Y, He Z, Huang H, Tian X, Wang G, Chen D, Ren Y, Jia L, Wang W, et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinMed. 2022;43:101226. doi:10.1016/j.eclinm.2021.101226.
   PubMedGoogle Scholar